Overview

Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of VX-765 in subjects with Treatment-resistant Partial Epilepsy
Phase:
Phase 2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated